Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of varenicline (a licensed cigarette smoking cessation aid) in helping users of smokeless tobacco to quit. DESIGN: Double blind, placebo controlled, parallel group, multicentre, randomised controlled trial. SETTING: Medical clinics (mostly primary care) in Norway and Sweden. PARTICIPANTS: Men and women aged ≥18 who used smokeless tobacco at least eight times a day, with no abstinence period over three months within one year before screening, who wanted to quit all tobacco use. Participants were excluded if they used any other form of tobacco (except smokeless tobacco) or medication to stop smoking within three months of screening or had any pre-existing medical or psychiatric condition. INTERVENTIONS: Varenicline 1 mg twice daily (titrated during the first week) or placebo for 12 weeks, with 14 weeks' follow-up after treatment. MAIN OUTCOME MEASURES: The primary end point was the four week continuous abstinence rate at the end of treatment (weeks 9-12) confirmed with cotinine concentration. A secondary end point was continuous abstinence rate for weeks 9-26. Safety and tolerability were also evaluated. RESULTS: 431 participants (213 varenicline; 218 placebo) were randomised and received at least one dose of study drug. Participants' demographics and baseline use of smokeless tobacco were similar (89% (189) and 90% (196), respectively, were men; mean age in both groups was 43.9; participants used smokeless tobacco products about 15 times a day, and about 80% first used smokeless tobacco within 30 minutes after awakening). Continuous abstinence rate at week 9-12 was higher in the varenicline group than the placebo group (59% (125) v 39% (85); relative risk 1.60, 95% confidence interval 1.32 to 1.87, P<0.001; risk difference 20%; number needed to treat 5). The advantage of varenicline over placebo persisted through 14 weeks of follow-up (continuous abstinence rate at week 9-26 was 45% (95) v 34% (73); relative risk 1.42, 1.08 to 1.79, P=0.012; risk difference 11%; number needed to treat 9). The most common adverse events in the varenicline group compared with the placebo group were nausea (35% (74) v 6% (14)), fatigue (10% (22) v 7% (15)), headache (10% (22) v 9% (20)), and sleep disorder (10% (22) v 7% (15)). Few adverse events led to discontinuation of treatment (9% (19) and 4% (9), respectively), and serious adverse events occurred in two (1%) and three (1%) participants, respectively. CONCLUSION: Varenicline can help people to give up smokeless tobacco and has an acceptable safety profile. The response rate in the placebo group in this study was high, suggesting a population less resistant to treatment than smokers. TRIAL REGISTRATION: NCT00717093.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Practice Guideline: Otitis Media with Effusion (Update)
Rosenfeld, R. M., Shin, J. J., Schwartz, S. R., Coggins, R., Gagnon, L., Hackell, J. M., Hoelting, D., Hunter, L. L., Kummer, A. W., Payne, S. C., et al. (2016) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815623467 · Cited by 2,006
A Clinical Practice Guideline for Treating Tobacco Use and Dependence: 2008 Update
(2008) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.04.009 · Cited by 1,410
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · cited 1×
“Varenicline could be expected to help users quit smokeless tobacco because of its mechanism of action. It can stimulate the release of sufficient dopamine to reduce craving and withdrawal while simultaneously acting as a partial antagonist, thereby blocking the binding of nicotine to the receptors―and consequently the…”
BackgroundTonstad, S., Davies, S., Flammer, M., Russ, C., & Hughes, J. (2010) · Drug Safety · doi:10.2165/11319180-000000000-00000 · Cited by 142 · cited 1×
“Neuropsychiatric adverse events occurred at the same rate in both treatment groups, with the exception of sleep disorder, abnormal dreams, and insomnia, which are well known side effects associated with varenicline, and are in accordance with a pooled safety analysis of 10 varenicline trials for smoking cessation.”
ResultSelf-citation
Cited by
Determinants of Tobacco Use and Renaming the FTND to the Fagerstrom Test for Cigarette Dependence
Fagerstrom, K. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntr137 · Cited by 976
Self-citationNicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies: A Network Meta-Analysis
Mills, E. J., Thorlund, K., Eapen, S., Wu, P., & Prochaska, J. J. (2014) · Circulation · doi:10.1161/circulationaha.113.003961 · Cited by 408
Singh, S., Loke, Y. K., Spangler, J. G., & Furberg, C. D. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.110218 · Cited by 286
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177
Fagerstrom, K., Russ, C., Yu, C.-R., Yunis, C., & Foulds, J. (2012) · Nicotine & Tobacco Research · doi:10.1093/ntr/nts018 · Cited by 174
Self-citationIARC Perspective on Oral Cancer Prevention
Bouvard, V., Nethan, S. T., Singh, D., Warnakulasuriya, S., Mehrotra, R., Chaturvedi, A. K., Chen, T. H.-H., Ayo-Yusuf, O. A., Gupta, P. C., Kerr, A. R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmsr2210097 · Cited by 162
Sterling, L. H., Windle, S. B., Filion, K. B., Touma, L., & Eisenberg, M. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002849 · Cited by 70
Tonstad, S., & Lawrence, D. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12543 · Cited by 44
Self-citation
Metadata
- Authors
- Fagerstrom, K., Gilljam, H., Metcalfe, M., Tonstad, S., & Messig, M.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2010-12-06
- Volume
- 341
- Issue
- dec06 1
- Pages
- c6549-c6549
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2048021420
- Cited by
- 89
- References
- 8
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.